{
    "clinical_study": {
        "@rank": "51803", 
        "arm_group": [
            {
                "arm_group_label": "IM vaccine in the past 3 years", 
                "description": "Those subjects that received the Fluzone ID influenza vaccine, and reported having received the IM influenza vaccine in the past three years."
            }, 
            {
                "arm_group_label": "no IM  vaccine in the past 3 years", 
                "description": "Patients that received the Fluzone ID vaccine and reported not receiving the IM influenza vaccine in the past 3 years."
            }, 
            {
                "arm_group_label": "vaccine administrators", 
                "description": "Those experienced vaccine administrators that administered the Fluzone ID vaccine, and were then surveyed concerning safety and overall satisfaction with the ID vaccine in comparison to the IM vaccine."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the acceptance of the Fluzone Intradermal (ID)vaccine in adults and vaccine\n      administrators in the United States.  Patients completed 2 surveys, one immediately\n      post-vaccination and one seven days later, that documented demographics and assessed their\n      injection pain, injection anxiety, speed of injection, overall satisfaction, and preference\n      for next year's vaccine. Vaccine administrators completed one survey assessing ease of\n      vaccine preparation and administration, time required to administer, and safety/risk of\n      needle stick injury for patient and administrator."
        }, 
        "brief_title": "Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "Patient Response to Fluzone ID Vaccine", 
        "detailed_description": {
            "textblock": "Patients were divided into two groups:  1) those that reported receiving the intramuscular\n      (IM) influenza vaccine in the past 3 years; and 2) those that reported not receiving the IM\n      influenza vaccine in the past 3 years.  The survey responses were compared between the two\n      groups. In addition, the subjects that reported receiving the IM vaccine in the past 3 years\n      were asked to compare their experience with the IM vaccine versus the ID vaccine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Age 18 -64 years of age Desire to receive the Fluzone Intradermal\n        vaccine to protect against influenza. -\n\n        Exclusion Criteria:Less than 18 years of age, or 65 years of age and older. Desire to\n        receive the Fluzone Intramuscular vaccine to protect against influenza.\n\n        problems of the immune system, current illness, severe allergy to eggs, severe (life\n        threatening) allergies, history of having Guillain-Barre Syndrome (a severe paralytic\n        illness) or having received a flu vaccine in the past three months.\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "community sample"
            }
        }, 
        "enrollment": {
            "#text": "249", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01716130", 
            "org_study_id": "M0611"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Fluzone Intradermal vaccine", 
        "lastchanged_date": "October 24, 2012", 
        "link": {
            "description": "Touro University California Web Site", 
            "url": "http://www.tu.edu"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Vallejo", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94592"
                }, 
                "name": "Touro University California"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators", 
        "other_outcome": {
            "description": "Using a survey tool, patients receiving the Fluzone ID vaccine were separated into 2 groups:  1) those that reported receiving the IM influenza vaccine in the past 3 years; and 2) those that reported not receiving the IM influenza vaccine in the past 3 years. All subject's satisfaction was assessed by survey immediately post-vaccination and 7 days later. Survey responses were compared between the 2 groups. The group that reported receiving the IM influenza vaccine in the past 3 years was asked to compare their experience with the ID vaccine in comparison to the IM vaccine.", 
            "measure": "Overall satisfaction with the Fluzone ID vaccine in two cohort groups", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "overall_official": {
            "affiliation": "Touro University, California", 
            "last_name": "James E Foy, D.O.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Overall patient satisfaction was assessed immediately post-vaccination and seven days later by patient survey.", 
            "measure": "Overall patient satisfaction with intradermal vaccine", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01716130"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Touro University, California", 
            "investigator_full_name": "James E. Foy, D.O.", 
            "investigator_title": "Professor of Pediatrics, Touro University College of Osteopathic Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Vaccine administrators (#8)completed a survey rating the ID vaccine in comparison to the IM vaccine in terms of ease of vaccine preparation, time required to administer the vaccine, and safety/needle stick risk for patients and administrators.", 
            "measure": "Overall satisfaction with the Fluzone ID vaccine by vaccine administrators", 
            "safety_issue": "Yes", 
            "time_frame": "seven days"
        }, 
        "source": "Touro University, California", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Touro University, California", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}